On May 13, 2026, Milestone announced financial results for the first quarter ended March 31, 2026. The company reported a net loss of $26.1 million, or $0.20 per share, compared with a net loss of $20.8 million, or $0.31 per share, in the same quarter a year earlier. Although the per-share loss improved year over year, the net loss widened because of higher commercial spending related to the CARDAMYST launch. Milestone Pharmaceuticals Inc. (NASDAQ: MIST) Q1 Earnings Miss: CARDAMYST Launch Begins as Cash Run ...

Milestone Pharmaceuticals NASDAQ: MIST said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibrillation with rapid ventricular rate. Get MIST alerts: Oliveto said Milestone made the product available through retail pharmacies by the end of January and began promotion in earnest in mid-February, including de ...

Milestone Pharmaceuticals (NasdaqGS:MIST) Q1 2026 Earnings call May 13, 2026 08:30 AM ET Company Participants Amit Hasija - CFO and EVP of Corporate Development Brandon Folkes - Managing Director Joseph Oliveto - President and CEO Lorenz Muller - CCO Michael Wood - Managing Director Mohit Bansal - Managing Director Ritu Baral - Managing Director Ted Tenthoff - Managing Director Tiago Fauth - Managing Director Conference Call Participants None - Analyst Operator Ladies and gentlemen, good morning, and welcom ...

Milestone Pharmaceuticals (NasdaqGS:MIST) Q1 2026 Earnings call May 13, 2026 08:30 AM ET Company Participants Amit Hasija - CFO and EVP of Corporate Development Brandon Folkes - Managing Director Joseph Oliveto - President and CEO Lorenz Muller - CCO Michael Wood - Managing Director Mohit Bansal - Managing Director Ritu Baral - Managing Director Ted Tenthoff - Managing Director Tiago Fauth - Managing Director Conference Call Participants None - Analyst Operator Ladies and gentlemen, good morning, and welcom ...

Milestone Pharmaceuticals (NasdaqGS:MIST) Q1 2026 Earnings call May 13, 2026 08:30 AM ET Speaker7Ladies and gentlemen, good morning, and welcome to the Milestone Pharma First Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone requires operator assistance during the conference, please signal the operator by pressing star and zero on your telephone keypad. As a reminder, this conferen ...

Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of $0.06. This compares to a loss of $0.31 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -433.33%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.18 per share when it actually produced a loss of $0.16, delivering a surprise of +11.11%. Over the last four quarters, the ...

MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the first quarter ending March 31, 2026, and provided corporate and regulatory updates. "We're excited to report on our first quarter of sales for CARDAMYST for paroxysmal supraventricular tachycardia, or PSVT. Healthcare professionals' initial rea ...